What happened
Wowtale reports that Adaptyv Bio raised a $40 million Series A led by Highland Europe, with ACE Ventures, byFounders and Y Combinator also participating. The Lausanne company provides an automated laboratory service in which customers submit digital protein sequences and receive experimental validation data. The source says the company plans to expand its laboratory capacity and open a London location.
Wowtale reports that Adaptyv Bio, based in Lausanne, Switzerland, raised a $40 million Series A led by Highland Europe. According to the article, ACE Ventures, which led the company’s $8 million seed round in November 2024, also participated, alongside byFounders and Y Combinator. The funding announcement is the central new business development in the source. Wowtale does not cite a public filing or independently verify the financing, and the article does not provide the terms of the round, Adaptyv’s valuation, or the investors’ own statements.
The company’s reported product is a laboratory service for AI-designed proteins. Wowtale says customers submit a protein design as a digital sequence through a web platform or application programming interface. Adaptyv then makes the DNA in-house, expresses the protein without using living cells, measures whether it binds to a target using surface plasmon resonance, and returns quality-controlled experimental data. These details describe the workflow reported by the outlet; the source does not provide independent documentation of throughput, error rates, turnaround times, pricing, or the proportion of customer designs that receive usable results.
Wowtale reports that Adaptyv’s revenue grew roughly tenfold in the 18 months after its seed round and that its team tripled. The article says the company now has more than 100 customers, including frontier AI labs, top-five pharmaceutical companies and AI-native drug-discovery startups. It also reports that the company’s public API is integrated with Boltz, Chai, Cradle, Tamarind, Latent Labs and Benchling. Those customer, revenue and integration claims are not independently confirmed in the supplied material, and the source does not define revenue, explain the customer-count methodology, or identify which organizations are paying customers.
The reported expansion plan has two parts. Wowtale says Adaptyv intends to triple laboratory capacity by the end of 2026, open a London lab and office in the fourth quarter of 2026, and grow its team from 25 to about 60 people. The article says the company wants to extend its work from binding validation into developability and broader biophysical characterization, then into modalities such as peptides, antibody-drug conjugates and degraders, and eventually cell-based function. The source does not establish whether these milestones are funded, contracted, approved or technically demonstrated.
Source details: en.wowtale.net ↗
Why it matters
AI systems can generate protein designs quickly, but the source describes physical validation as a slower bottleneck. If Adaptyv’s reported service works at the stated scale, it could give drug-discovery teams faster access to experimental evidence about whether designed proteins are expressed and bind their targets. The broader significance remains uncertain because the article does not independently document the company’s operations, customer contracts or experimental results.
The source frames Adaptyv’s business around a specific problem in AI-assisted biology: generating a candidate protein sequence is faster than determining whether that sequence produces a correctly expressed protein with the desired binding behavior. That distinction matters because a computational design is not, by itself, a therapeutic result. Physical testing supplies evidence about whether a design behaves as intended, but the article does not show that the reported workflow improves clinical success, safety or drug-development timelines.
If the reported model is reproducible, a shared automated validation service could lower the amount of specialized laboratory infrastructure required by teams developing protein designs. It could also make it easier to compare many candidates using a common workflow. Wowtale reports that the company’s API is being used in design-and-validation pipelines involving organizations such as Anthropic, Google DeepMind and Chai Discovery, but the supplied article does not independently confirm those relationships, their commercial terms or the extent of their use.
The article highlights results from an Anthropic project called Claude Science. Wowtale reports that Anthropic used Claude models to design proteins across 16 targets drawn from Adaptyv’s public competitions, with sequences sent anonymously to the Lausanne lab. The source says 95% of 1,320 designs were expressed successfully and that 354, or 26.8%, bound their target; it also says Claude matched or exceeded expert human hit rates on most targets and exceeded them by more than three times on one target. These are important claims, but they remain claims reported by Wowtale: the source does not reproduce the study, identify the targets, describe the comparison group or provide enough methodological detail to assess the results independently.
The investment also illustrates a division emerging around AI drug discovery. Wowtale describes companies such as Chai Discovery, Latent Labs and Isomorphic Labs as expanding the design layer, while Adaptyv is focusing on the experimental validation layer. The source also mentions other efforts to automate laboratory work, including Recursion’s reported LabClaw architecture and a University of Toronto consortium’s fleet of self-driving robots. These comparisons provide context, but they do not establish that Adaptyv’s approach is more capable, less expensive or more reliable than competing systems.
What to watch next
The key questions are whether Adaptyv can deliver its planned capacity expansion, whether its reported customers continue using the service, and whether it can validate properties beyond binding. Readers should also watch for independent publication of the reported Anthropic results, clearer information about study design and controls, and evidence that faster validation produces useful therapeutic candidates rather than simply more tested designs.
The first test is execution of the capacity plan. Wowtale reports that Adaptyv wants to triple its laboratory capacity by the end of 2026 and open a London facility in the fourth quarter. Useful follow-up reporting would establish whether those facilities open on schedule, how many experiments they can run, how much human intervention remains necessary, and whether quality control is consistent across sites. None of those operational details is available in the supplied source.
The second test is the quality and usefulness of the experimental evidence. Binding is only one property of a potential therapeutic protein. Wowtale says Adaptyv plans to add developability and full biophysical characterization, followed by work on additional modalities and cell-based function. It remains unknown whether the company has validated those capabilities, whether they are available to customers, and how results from its assays translate into decisions about advancing or abandoning a candidate.
The Anthropic case study warrants particular scrutiny because it is the article’s main evidence of performance. Follow-up coverage should seek the underlying study, protocols, target list, anonymization procedure, definition of a successful expression, binding thresholds, expert baseline and any negative or inconclusive results. It would also be important to determine whether the reported hit rates were selected from a competition dataset or represent prospective performance on previously unseen designs. The supplied source does not answer those questions.
Finally, readers should watch whether the financing produces durable public or practical impact. Wowtale reports that the company serves more than 100 customers and that Roche and Novo Nordisk run therapeutic design cycles roughly four times faster using Adaptyv’s lab, but those claims are not independently confirmed here. Future evidence should clarify the companies’ roles, the baseline used for the speed comparison, the costs involved and whether faster cycles lead to validated drug candidates, patents, clinical programs or other measurable outcomes.
